ClinicalTrials.gg
CompletedNCT00319696RAPIDS 2 OLUpdated Feb 4, 2025Results posted

Bosentan in Digital Ulcers

A Phase 3 interventional study of Bosentan 62.5 mg and Bosentan 125 mg in Digital Ulcers, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jul 2004, registered Apr 2006).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
116
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of the study is to collect long-term efficacy, tolerability and safety data of bosentan in Systemic Sclerosis (SSc) patients suffering from ischemic digital ulcers (DUs).

02

Conditions studied

  • Digital Ulcers

Keywords

  • digital ulcers
  • systemic sclerosis
  • finger ulcers
  • bosentan
  • open label
03

In context

digital ulcers

29 studies on the registry are indexed under digital ulcers; 7 are open to participants now.

This study's enrollment of 116 is above the median of 40 across 23 interventional studies indexed under digital ulcers.

Browse digital ulcers studies →

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with SSc according to the classification criteria of the American College of Rheumatology
  2. SSc patients with at least one DU at baseline qualifying as a CU (see definition section 3.2.2)
  3. CU occurred \< 3 months and > 1 week prior to randomization. The subset of patients with SSc felt to be at high risk for DUs will be identified in the screening period but will not be eligible for enrollment until a CU has developed
  4. Male or female patients >/= 18 years of age
  5. Women of must have a negative pre-treatment pregnancy test and use a reliable method of during study treatment and for at least 3 months after study treatment termination
  6. Women not of childbearing potential are defined as (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile
  7. Signed .

Exclusion criteria

Exclusion Criteria:

  1. DUs due to condition other than SSc
  2. Severe PAH (WHO class III and IV)
  3. Systolic blood pressure \< 85 mmHg
  4. concentration \< 75% of the lower limit of the normal range
  5. and/or ALT values greater than 3 times the
  6. Moderate to severe hepatic impairment, i.e., Class B or C
  7. Severe malabsorption or any severe organ failure (e.g., lung, kidney) or any life-threatening condition
  8. Pregnancy or breast-feeding
  9. Previous treatment with bosentan
  10. Treatment with any of the following: glibenclamide (glyburide), fluconazole, cyclosporine A, tacrolimus and any other calcineurin inhibitor 1 week prior to randomization
  11. Local injection of botulinum toxin in an affected finger 1 month prior to randomization
  12. Treatment with parenteral prostanoids (prostaglandin E, epoprostenol, treprostinil sodium or other prostacyclin analogs) 3 months prior to randomization
  13. Treatment with inhaled or oral prostanoids one month prior to randomization
  14. Systemic antibiotics to treat infection of DUs 2 weeks prior to randomization
  15. Treatment with phosphodiesterase inhibitors such as sildenafil, except for intermittent treatment of male erectile dysfunction
  16. Body weight \< 40 kg
  17. Patient with conditions that prevent compliance with the protocol or adhering to therapy
  18. Patient who received an product within 1 month preceding screening
  19. Known to bosentan or any of the .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Bosentan

    Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter

    Drug: Bosentan 62.5 mg · Drug: Bosentan 125 mg

Interventions

  • Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)

  • Bosentan 125-mg oral tablets administered b.i.d. (target dose)

06

What researchers measure

Primary outcomes

  1. Time to Complete Healing of Each Baseline DU

    Time frame: Baseline to healing

  2. Time to Complete Healing of Each New DU

    Time frame: New DU occurence to healing

  3. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Dressing

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  4. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Arising

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  5. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Eating

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  6. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Walking

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  7. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Hygiene

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  8. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Reach

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  9. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Grip

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  10. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity

    SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

    Time frame: 80 weeks

  11. Mean Changes From Baseline at Each 16 Week Interval up to Week 80 in Overall Hand Pain Related to Finger Ulcers

    Overall hand pain related to finger ulcers was assessed by the patient using a Visual Analogue Scale. Patients were instructed to score their pain by marking on the continuous 10-cm scale, where 0 (left) was no pain and 100 (right) very severe pain, in response to the question, "How much pain have you had because of your finger ulcers in the past week?" The investigator measured the distance in millimeters between 0 and the patient mark with the ruler provided and recorded the distance.

    Time frame: 80 weeks

  12. Mean Change From Baseline at Each 16 Week Interval up to Week 80 in the UK Systemic Sclerosis Functional Score (UKFS)

    UKFS relates to upper and lower extremity function and muscle weakness. For each item, the patient indicated the responses that best described their current ability: "able to perform in a normal manner," "able to perform with alteration in style," "can only manage with difficulty," and "impossible to achieve." Each response was given an integer from 0 (able to perform in a normal manner) to 3 (impossible to achieve), and the sum of individual responses provided an overall score of 0 to 33. Missing values were replaced with the worst value the patient reported on the other items at that visit.

    Time frame: 80 weeks

  13. Total Number of New Digital Ulcers (DUs) Per Patient Observed by the Investigator at Planned Visits

    The total number of new DUs per patient observed by the investigator at planned visits and new transient DUs recorded in the patient diary (a patient diary was used to record DUs that might appear and disappear between two planned visits) were assessed at each clinic visit

    Time frame: At planned visits up to week 80

Secondary outcomes

  1. Adverse Events up to 24 Hours After Last Study Medication

    Number of patients with at least one treatment-emergent adverse event. All adverse events that occurred after study drug initiation and up to 24 hours after study drug discontinuation were to be recorded.

    Time frame: 80 weeks

  2. Adverse Events Leading to Permanent Discontinuation of the Study Medication

    Number of patients with an adverse event leading to permanent discontinuation of the study treatment

    Time frame: 80 weeks

  3. Serious Adverse Events up to 28 Days After Last Study Medication

    Number of patients with at least one treatment-emergent serious adverse event (TESAE) were reported. TESAEs are serious AEs that occurred after study drug initiation and up to 28 days after study drug discontinuation. More details on the SAEs are provided in the specific Adverse Events Section

    Time frame: 80 weeks

07

Results

Posted Aug 8, 2012

Participant flow

Patients were enrolled at 33 centers in 7 countries (Canada, France, Germany, Italy, Switzerland, UK, and USA. The first patient enrolled and started treatment on 8 July 2004 and the last patient enrolled and started treatment on 20 October 2005.

Participant flow — Overall Study
MilestoneBosentan
Started116
Completed56
Not completed60
Withdrew: Adverse event36
Withdrew: Withdrawal of consent14
Withdrew: Administrative7
Withdrew: Lost to follow-up3

Outcome measures

PrimaryTime to Complete Healing of Each Baseline DU
Time frame:
Baseline to healing

No measurements were reported for this outcome.

PrimaryTime to Complete Healing of Each New DU
Time frame:
New DU occurence to healing

No measurements were reported for this outcome.

PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Dressing

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Dressing
scores on a scaleBosentan
change from baseline to week 16-0.3 ± 0.6
change from baseline to week 32-0.2 ± 0.7
change from baseline to week 48-0.1 ± 0.7
change from baseline to week 64-0.1 ± 0.7
change from baseline to week 80-0.1 ± 0.7
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Arising

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Arising
scores on a scaleBosentan
change from baseline to week 160.0 ± 0.6
change from baseline to week 32-0.0 ± 0.6
change from baseline to week 480.1 ± 0.6
change from baseline to week 640.1 ± 0.7
change from baseline to week 800.1 ± 0.6
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Eating

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Eating
scores on a scaleBosentan
change from baseline to week 16-0.2 ± 0.6
change from baseline to week 32-0.1 ± 0.7
change from baseline to week 48-0.2 ± 0.7
change from baseline to week 64-0.1 ± 0.6
change from baseline to week 80-0.1 ± 0.7
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Walking

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Walking
scores on a scaleBosentan
change from baseline to week 16-0.1 ± 0.6
change from baseline to week 320.0 ± 0.7
change from baseline to week 480.1 ± 0.7
change from baseline to week 640.1 ± 0.8
change from baseline to week 800.1 ± 0.8
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Hygiene

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Hygiene
scores on a scaleBosentan
change from baseline to week 16-0.0 ± 0.7
change from baseline to week 32-0.0 ± 0.8
change from baseline to week 48-0.0 ± 0.8
change from baseline to week 640.1 ± 0.7
change from baseline to week 800.2 ± 0.8
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Reach

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Reach
scores on a scaleBosentan
change from baseline to week 16-0.1 ± 0.7
change from baseline to week 320.0 ± 0.7
change from baseline to week 480.0 ± 0.8
change from baseline to week 640.1 ± 0.8
change from baseline to week 800.0 ± 0.7
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Grip

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Grip
scores on a scaleBosentan
change from baseline to week 16-0.1 ± 0.7
change from baseline to week 32-0.2 ± 0.7
change from baseline to week 48-0.1 ± 0.7
change from baseline to week 64-0.1 ± 0.7
change from baseline to week 80-0.1 ± 0.7
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity

SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.

Time frame:
80 weeks
Reported as:
Mean · scores on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity
scores on a scaleBosentan
change from baseline to week 16-0.2 ± 0.5
change from baseline to week 32-0.1 ± 0.7
change from baseline to week 48-0.1 ± 0.7
change from baseline to week 64-0.1 ± 0.7
change from baseline to week 80-0.1 ± 0.6
PrimaryMean Changes From Baseline at Each 16 Week Interval up to Week 80 in Overall Hand Pain Related to Finger Ulcers

Overall hand pain related to finger ulcers was assessed by the patient using a Visual Analogue Scale. Patients were instructed to score their pain by marking on the continuous 10-cm scale, where 0 (left) was no pain and 100 (right) very severe pain, in response to the question, "How much pain have you had because of your finger ulcers in the past week?" The investigator measured the distance in millimeters between 0 and the patient mark with the ruler provided and recorded the distance.

Time frame:
80 weeks
Reported as:
Mean · mm
Mean Changes From Baseline at Each 16 Week Interval up to Week 80 in Overall Hand Pain Related to Finger Ulcers
mmBosentan
change from baseline to week 16-21.59 ± 28.02
change from baseline to week 32-28.16 ± 32.64
change from baseline to week 48-21.90 ± 32.09
change from baseline to week 64-22.96 ± 33.27
change from baseline to week 80-24.29 ± 36.55
PrimaryMean Change From Baseline at Each 16 Week Interval up to Week 80 in the UK Systemic Sclerosis Functional Score (UKFS)

UKFS relates to upper and lower extremity function and muscle weakness. For each item, the patient indicated the responses that best described their current ability: "able to perform in a normal manner," "able to perform with alteration in style," "can only manage with difficulty," and "impossible to achieve." Each response was given an integer from 0 (able to perform in a normal manner) to 3 (impossible to achieve), and the sum of individual responses provided an overall score of 0 to 33. Missing values were replaced with the worst value the patient reported on the other items at that visit.

Time frame:
80 weeks
Reported as:
Mean · score on a scale
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in the UK Systemic Sclerosis Functional Score (UKFS)
score on a scaleBosentan
change from baseline to week 16-1.37 ± 3.64
change from baseline to week 32-1.25 ± 4.01
change from baseline to week 48-0.89 ± 4.98
change from baseline to week 64-1.17 ± 4.00
change from baseline to week 80-0.45 ± 4.66
PrimaryTotal Number of New Digital Ulcers (DUs) Per Patient Observed by the Investigator at Planned Visits

The total number of new DUs per patient observed by the investigator at planned visits and new transient DUs recorded in the patient diary (a patient diary was used to record DUs that might appear and disappear between two planned visits) were assessed at each clinic visit

Time frame:
At planned visits up to week 80
Reported as:
Number · number of new digital ulcers
Total Number of New Digital Ulcers (DUs) Per Patient Observed by the Investigator at Planned Visits
number of new digital ulcers0 New UlcersAt Least 1 New UlcerAt Least 2 New UlcersAt Least 3 New UlcersAt Least 4 New UlcersAt Least 5 New Ulcers
Week 0-4852917643
Week 4-8733415643
Week 8-16634022975
Week 16-246436171142
Week 24-325641221284
Week 32-40593515754
Week 40-485236201153
Week 48-565037181375
Week 56-64483814743
Week 64-7251352415108
Week 72-80513218942
SecondaryAdverse Events up to 24 Hours After Last Study Medication

Number of patients with at least one treatment-emergent adverse event. All adverse events that occurred after study drug initiation and up to 24 hours after study drug discontinuation were to be recorded.

Time frame:
80 weeks
Reported as:
Number · participants
Adverse Events up to 24 Hours After Last Study Medication
participantsBosentan
Adverse Events up to 24 Hours After Last Study Medication111
SecondaryAdverse Events Leading to Permanent Discontinuation of the Study Medication

Number of patients with an adverse event leading to permanent discontinuation of the study treatment

Time frame:
80 weeks
Reported as:
Number · participants
Adverse Events Leading to Permanent Discontinuation of the Study Medication
participantsBosentan
Adverse Events Leading to Permanent Discontinuation of the Study Medication36
SecondarySerious Adverse Events up to 28 Days After Last Study Medication

Number of patients with at least one treatment-emergent serious adverse event (TESAE) were reported. TESAEs are serious AEs that occurred after study drug initiation and up to 28 days after study drug discontinuation. More details on the SAEs are provided in the specific Adverse Events Section

Time frame:
80 weeks
Reported as:
Number · Participants
Serious Adverse Events up to 28 Days After Last Study Medication
ParticipantsBosentan
Serious Adverse Events up to 28 Days After Last Study Medication45

Adverse events

Collected over 80 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan6/116 (5.2%)45/116 (38.8%)111/116 (95.7%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventBosentan
PNEUMONIAInfections and infestations6/116
DYSPNOEARespiratory, thoracic and mediastinal disorders6/116
SKIN ULCERSkin and subcutaneous tissue disorders5/116
INFECTED SKIN ULCERInfections and infestations4/116
PERIPHERAL ISCHAEMIAVascular disorders4/116
CELLULITISInfections and infestations2/116
DEVICE RELATED INFECTIONInfections and infestations2/116
SEPSISInfections and infestations2/116
PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders2/116
PULMONARY HYPERTENSIONRespiratory, thoracic and mediastinal disorders2/116
Most frequent other events
Showing 10 of 38
Most frequent other events
EventBosentan
SKIN ULCERSkin and subcutaneous tissue disorders26/116
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations24/116
ARTHRALGIAMusculoskeletal and connective tissue disorders22/116
DIARRHOEAGastrointestinal disorders21/116
INFECTED SKIN ULCERInfections and infestations21/116
LOCALISED INFECTIONInfections and infestations17/116
COUGHRespiratory, thoracic and mediastinal disorders15/116
HEADACHENervous system disorders14/116
RASHSkin and subcutaneous tissue disorders14/116
NASOPHARYNGITISInfections and infestations13/116

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bosentan
Mean49.3 ± 12.0
Age, Customized
Age, Customized(Participants)Bosentan
Between 24 and 79 years116
Sex: Female, Male
Sex: Female, Male(Participants)Bosentan
Female87
Male29
Region of Enrollment
Region of Enrollment(Participants)Bosentan
Canada11
France10
Germany9
Italy9
Switzerland4
United Kingdom6
United States67
Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score
Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score(score on a scale)Bosentan
Dressing1.3 ± 0.9
Arising0.5 ± 0.8
Eating1.5 ± 1.0
Walking0.5 ± 0.7
Hygiene0.9 ± 1.0
Reach1.1 ± 0.9
Grip1.1 ± 0.8
Activity1.0 ± 0.9
Overall hand pain
Overall hand pain(mm)Bosentan
Mean58.62 ± 29.80
United Kingdom Scleroderma Functional Score (UKFS)
United Kingdom Scleroderma Functional Score (UKFS)(score on a scale)Bosentan
Mean11.06 ± 7.50
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2004 to primary completion in Jan 2009, 54 months.

Results were first posted in Aug 2012, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2006
First posted
Apr 27, 2006
StartActual
Jul 8, 2004
Primary completionActual
Jan 22, 2009
CompletionActual
Jan 22, 2009
Results first posted
Aug 8, 2012
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00319696
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Jul 8, 2004
Primary completion
Jan 22, 2009
Completion
Jan 22, 2009
Results posted
Aug 8, 2012
Last update
Feb 4, 2025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion